Pharmacogenomics, Adverse Drug Reactions, Medication Safety, and Adherence

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/69

flashcard set

Earn XP

Description and Tags

Vocabulary practice flashcards covering fundamental pharmacogenomics, adverse drug reactions, medication error categorization, error prevention models, and medication adherence strategies from Larkin University's PA 5111 course.

70 Terms

1
New cards

Pharmacogenomics

The science of examining inherited variations in genes that determine a person's response to a drug, integrating genetics and pharmacology to design treatments with improved efficacy and reduced adverse reactions.

2
New cards

Nucleotide

A subunit of nucleic acids (DNA and RNA) consisting of a nitrogen base (adenine, guanine, thymine, cytosine, or uracil), a five-carbon sugar (deoxyribose or ribose), and a phosphate group.

3
New cards

Chromosome

A tightly packed structure within the cell nucleus composed of DNA and proteins that contains genes; human cells contain 23 pairs.

4
New cards

Gene

A specific sequence of nucleotides that provides the instructions or recipe to code for a single protein, often termed the blueprint of life.

5
New cards

Allele

A specific variant or form of a gene; can be wild-type (most commonly occurring) or a variant form, designated with star-nomenclature such as *1, *2, or *3.

6
New cards

Genotype

The set of unique genes or allele combinations (e.g., CYP2C19 1/3) that determine a specific trait in an individual.

7
New cards

Phenotype

The observable outward trait or clinical manifestation of a genotype, such as hair color, sickle cell disease, or fast versus slow drug metabolism.

8
New cards

Haplotype

A group of genes or DNA variations located on the same chromosome that are inherited together from a single parent (e.g., VKORC1 haplotypes in warfarin response).

9
New cards

Single Nucleotide Polymorphism (SNP)

The most common genetic alteration in DNA, characterized by a single base-pair change (e.g., C replaced by G), accounting for the majority of individual variability in drug response.

10
New cards

Structural Variation (SV)

Large-scale genetic polymorphisms involving substantial segments of DNA, such as gene duplications that can lead to ultra-rapid metabolism.

11
New cards
<p>Autosomal Dominant Inheritance</p>

Autosomal Dominant Inheritance

A pattern of inheritance where a single copy of a mutated allele from one parent produces the affected phenotype, resulting in a 50% chance of offspring being affected.

12
New cards
<p>Autosomal Recessive Inheritance</p>

Autosomal Recessive Inheritance

A pattern of inheritance requiring two copies of a mutated gene (one from each parent) to produce the phenotype, yielding a 25% chance of an affected child and a 50% chance of a carrier child.

13
New cards

Poor Metabolizer (PM)

An individual with significantly reduced or absent drug-metabolizing enzyme activity, causing elevated active drug levels or failure to convert prodrugs to active metabolites.

14
New cards

Ultra-rapid Metabolizer (UM)

An individual with abnormally elevated enzyme activity (often due to gene duplication), causing rapid drug clearance or rapid over-conversion of a prodrug to its active form.

15
New cards
<p>Genetic Variability in Metabolism (CYP450)</p>

Genetic Variability in Metabolism (CYP450)

Variations in enzyme expression where deleted genes produce no enzyme, single genes yield normal/unstable enzymes, and duplicated genes result in higher enzyme levels.

16
New cards

HLA-B*1502

A human leukocyte antigen allele prevalent in Asian populations that increases the risk of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) 113.4-fold when exposed to carbamazepine.

17
New cards

HLA-B*5701

An allele strongly associated with fatal hypersensitivity reactions to the antiretroviral abacavir; screening is required before initiation and use is contraindicated if positive.

18
New cards

HLA-B*5801

An allele linked to an elevated risk of severe Stevens-Johnson syndrome upon allopurinol exposure, particularly in patients of Korean, Han Chinese, or Thai ancestry.

19
New cards

CYP2C19 Polymorphism (Clopidogrel)

A genetic variation affecting clopidogrel bioactivation; patients carrying loss-of-function *2 or *3 alleles cannot adequately form the active antiplatelet metabolite, increasing cardiovascular risk.

20
New cards

CYP2D6 Polymorphism (Codeine)

Variation in the enzyme converting codeine to morphine; ultra-rapid metabolizers face life-threatening opioid toxicity, leading to FDA contraindications for children post-tonsillectomy/adenoidectomy.

21
New cards

VKORC1 and CYP2C9 Variants (Warfarin)

Polymorphisms (CYP2C92, CYP2C93, and VKORC1 G > A) that decrease warfarin clearance and increase target sensitivity, necessitating lower initial dosages to prevent bleeding.

22
New cards

HER2 Testing (Trastuzumab)

A pharmacogenomic test required to identify overexpression of human epidermal growth factor receptor 2; trastuzumab is ineffective if tumor status is HER2 negative.

23
New cards

KRAS Mutation Testing (Cetuximab)

Diagnostic testing for colorectal cancer where only KRAS wild-type (mutation-negative) patients respond to EGFR inhibitors like cetuximab.

24
New cards

DPD Deficiency

A dihydropyrimidine dehydrogenase deficiency that severely impairs clearance of capecitabine and fluorouracil, precipitating fatal hematologic, gastrointestinal, and neurotoxicities.

25
New cards

Thiopurine Methyltransferase (TPMT)

An enzyme responsible for metabolizing azathioprine; low or absent activity dramatically increases bone marrow toxicity, resulting in life-threatening myelosuppression.

26
New cards

Adverse Drug Reaction (ADR)

Any unintended, noxious, or harmful pharmacologic effect of a drug that occurs when the medication is administered correctly at recommended dosages.

27
New cards

Medication Error

Any preventable event that may cause or lead to inappropriate medication use or patient harm while the medication is in the control of the healthcare professional, patient, or consumer.

28
New cards

Type A Reaction

A predictable, dose-dependent adverse drug reaction related to the known pharmacology of the drug, accounting for approximately 80% of all ADRs (e.g., orthostatic hypotension from doxazosin).

29
New cards

Type B Reaction

An unpredictable, dose-independent adverse drug reaction influenced by patient-specific factors, comprising drug allergies, pseudoallergic reactions, intolerances, and idiosyncratic responses.

30
New cards

Drug Intolerance

A predictable, non-immune adverse reaction occurring at subtherapeutic or normal therapeutic doses that is not life-threatening (e.g., nausea from codeine, diarrhea from metformin).

31
New cards

Pseudoallergic Reaction

A non-immune-mediated reaction that mimics an allergic response through direct histamine release without specific antibody activation (e.g., itching from opioids or vancomycin infusion reaction).

32
New cards

Type I Hypersensitivity Reaction

An immediate, IgE-mediated allergic reaction occurring within seconds to minutes of re-exposure, where cross-linking on mast cells and basophils triggers histamine release.

33
New cards

Type II Hypersensitivity Reaction

A cytotoxic reaction mediated by IgG or IgM antibodies directed against cell-surface bound drugs, leading to complement-mediated lysis (e.g., penicillin-induced hemolytic anemia, HIT).

34
New cards

Type III Hypersensitivity Reaction

An immune-complex-mediated reaction occurring 1 to 3 weeks after exposure, characterized by antigen-antibody complexes depositing in tissues and inciting inflammation (e.g., serum sickness, drug-induced lupus).

35
New cards

Type IV Hypersensitivity Reaction

A delayed cell-mediated immune response driven by T-lymphocytes rather than antibodies, presenting 48 hours to weeks after exposure (e.g., contact dermatitis, SJS/TEN, DRESS).

36
New cards

Urticaria

A vascular skin reaction characterized by pruritic, raised red or pink patches (wheals/hives) of varied shapes and sizes.

37
New cards

Angioedema

Submucosal and deep dermal swelling caused by localized edema in cutaneous, mucosal, and submucosal tissue, often affecting the lips, tongue, and throat.

38
New cards

Boxed Warning

The FDA's strongest warning category, marked by a black border around the text, indicating a significant risk of death or permanent disability associated with a medication.

39
New cards

Contraindication

A clinical situation or patient characteristic where a medication must not be administered because the risks clearly outweigh any possible therapeutic benefit.

40
New cards

Risk Evaluation and Mitigation Strategies (REMS)

FDA-mandated safety programs developed by manufacturers to manage known serious risks, incorporating elements such as prescriber certification, registries, and monitoring (e.g., iPLEDGE for isotretinoin).

41
New cards

Medication Guide

An FDA-approved, non-technical patient handout detailing serious adverse effects, required by law to be dispensed with specific outpatient prescriptions and every refill.

42
New cards
<p>Naranjo Scale</p>

Naranjo Scale

A validated 10-question causality assessment algorithm that scores the probability that an adverse event is drug-induced (>9 = definite, 5-8 = probable, 1-4 = possible, ≤0\le 0 = doubtful).

43
New cards

MedWatch

The FDA's voluntary safety reporting program for healthcare providers and consumers to submit reports of adverse events involving drugs, biologics, devices, and supplements to FAERS.

44
New cards

To Err is Human

The landmark 1999 Institute of Medicine (IOM) report highlighting the widespread prevalence and financial impact of medical errors, catalyzing national safety research and legislation.

45
New cards

Error of Execution

A medical error where a correct and planned action fails to be completed as intended.

46
New cards

Error of Planning

A medical error where an inappropriate or wrong plan was selected and carried out.

47
New cards

Error of Commission

A medical error characterized by taking the wrong action, such as administering penicillin to a patient with a documented penicillin allergy.

48
New cards

Error of Omission

A medical error characterized by failing to take an appropriate action, such as missing a scheduled drug dose or failing to order required laboratory monitoring.

49
New cards

Sentinel Event

An unexpected adverse event resulting in death, permanent harm, or severe temporary harm that requires immediate investigation and root cause analysis.

50
New cards

Close Call (Near Miss)

A medication-related event that had the capacity to cause patient harm but was intercepted or did not cause injury.

51
New cards
<p>NCC MERP Index</p>

NCC MERP Index

A standardized categorization system classifying medication error severity from Category A (circumstances with capacity to cause error) through Category I (error resulting in patient death).

52
New cards

Computerized Physician Order Entry (CPOE)

An electronic prescribing system that directly enters medical orders to reduce illegible handwriting and transcription errors, demonstrated to reduce overall error rates by 48%.

53
New cards

Barcode Medication Administration (BCMA)

A bedside scanning safety technology that verifies the Five Rights of medication administration (right patient, drug, dose, time, and route) before dosing.

54
New cards
<p>Tall Man Lettering</p>

Tall Man Lettering

The practice of using capitalized typography for distinct syllables in look-alike and sound-alike generic drug names (e.g., buPROPion vs busPIRone) to prevent dispensing mix-ups.

55
New cards
<p>Joint Commission "Do Not Use" List</p>

Joint Commission "Do Not Use" List

A mandated list of error-prone abbreviations and notations (such as U, IU, QD, QOD, trailing zeros, lack of leading zeros, and MSO4) prohibited from medical records.

56
New cards

Medication Reconciliation

The formal process of compiling the most complete and accurate list of a patient's medications across transitions of care and comparing it against newly ordered therapy.

57
New cards
<p>Swiss Cheese Model</p>

Swiss Cheese Model

A system safety model illustrating that harm occurs only when defensive barriers (prescriber, pharmacist, nurse checks) all simultaneously fail, allowing an error trajectory to reach the patient.

58
New cards

Root Cause Analysis (RCA)

A structured retrospective investigation conducted after an adverse or sentinel event to identify underlying systemic vulnerabilities rather than assign individual blame.

59
New cards

Failure Modes and Effects Analysis (FMEA)

A proactive, prospective risk-assessment technique carried out before implementing a new healthcare process to identify potential failure points and prevent errors.

60
New cards

Just Culture

A safety culture framework that distinguishes between human error (managed by system redesign), at-risk behavior, and reckless negligence, promoting accountability without fear of unjust punishment.

61
New cards

Medication Compliance

A traditional term denoting a passive process where the patient conforms to prescriber directions, placing responsibility and blame entirely on the patient for deviations.

62
New cards

Medication Adherence

The degree to which a patient's behavior corresponds with agreed-upon recommendations from a healthcare provider, emphasizing an active partnership and shared decision-making.

63
New cards

Intentional Non-adherence

An active decision-making process where a patient purposefully chooses to deviate from prescribed therapy due to beliefs, perceived side effects, low trust, or health fears.

64
New cards

Unintentional Non-adherence

A passive failure to adhere to medication regimens caused by forgetfulness, cognitive issues, physical limitations, lack of financial resources, or complex schedules.

65
New cards
<p>Five Dimensions of Adherence</p>

Five Dimensions of Adherence

A World Health Organization framework categorizing adherence barriers into Social & Economic, Health Care System, Condition-Related, Therapy-Related, and Patient-Related factors.

66
New cards

Morisky Medication Adherence Scale (MMAS-8)

An 8-item self-report questionnaire assessing adherence behaviors, where a score of 8 indicates high adherence, 6 to 7 indicates medium adherence, and below 6 reflects low adherence.

67
New cards

SIMPLE Model

A multi-component adherence improvement strategy: Simplify regimen, Impart knowledge, Modify patient beliefs, Provide communication and trust, Leave the bias, and Evaluate adherence.

68
New cards
<p>Stages of Change (Transtheoretical Model)</p>

Stages of Change (Transtheoretical Model)

A behavioral readiness framework outlining progression through Precontemplation, Contemplation, Preparation, Action, and Maintenance, with Relapse viewed as a normal learning setback.

69
New cards

O.A.R.S.

The core communication skills of motivational interviewing: Open-ended questions, Affirmations, Reflective listening, and Summarizing.

70
New cards

Elicit-Provide-Elicit

A collaborative communication technique in which the provider asks permission and explores prior knowledge, provides new health information, and elicits the patient's understanding.